Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 2/20 | 0.46 |
| ▸ | CYP17A1 | P05093 | 4/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
| ▸ | ATR | Q13535 | 1/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.38 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.38 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.38 |
| ▸ | IDO1 | P14902 | 1/20 | 0.36 |
| ▸ | LCK | P06239 | 1/20 | 0.36 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14428036 | 0.86 | NAMPT (0.54) | NAMPTCYP17A1RAB9ACA12CA1 | |
| SCHEMBL3119352 | 0.83 | CA12 (0.45) | NAMPTCYP17A1RAB9ACA12CA1 | |
| SCHEMBL1710464 | 0.80 | NAMPT (0.49) | NAMPTCYP17A1CA12CA1CA9 | |
| SCHEMBL29674394 | 0.80 | NAMPT (0.49) | NAMPTCYP17A1CA12CA1CA9 | |
| SCHEMBL12735928 | 0.80 | NAMPT (0.49) | NAMPTCYP17A1CA12CA1CA9 | |
| SCHEMBL7822474 | 0.79 | ATM (0.51) | NAMPTCYP17A1HDAC3HDAC1HDAC2 | |
| SCHEMBL31145167 | 0.79 | ATM (0.51) | NAMPTCYP17A1HDAC3HDAC1HDAC2 | |
| SCHEMBL1502539 | 0.79 | NAMPT (0.48) | NAMPTCYP17A1RAB9ACA12CA1 | |
| SCHEMBL8444197 | 0.79 | NAMPT (0.48) | NAMPTCYP17A1CA12CA1CA9 | |
| SCHEMBL12313962 | 0.79 | NAMPT (0.48) | NAMPTCYP17A1CA12CA1CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4630115-A1 | THERAPEUTIC COMPOUNDS | Sanofi (FR) | 2025-10-15 | — | — | EP | disclosed |
| CN-115867535-B | Substituted benzamides as modulators of TREX1 | 星座制药公司 | 2024-12-17 | — | — | CN | disclosed |
| US-20240383915-A1 | OXAZEPINE COMPOUNDS AND USES THEREOF IN THE TREATMENT OF CANCER | GENENTECH, INC. (US) | 2024-11-21 | — | — | US | disclosed |
| WO-2024121427-A1 | THERAPEUTIC COMPOUNDS | SANOFI (FR) | 2024-06-13 | — | — | WO | disclosed |
| EP-4320132-A1 | OXAZEPINE COMPOUNDS AND USES THEREOF IN THE TREATMENT OF CANCER | Genentech, Inc. (US) | 2024-02-14 | — | — | EP | disclosed |
| CN-117083279-A | Oxazepine compounds and their use in the treatment of cancer | 基因泰克公司 | 2023-11-17 | — | — | CN | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| WO-2022216762-A1 | OXAZEPINE COMPOUNDS AND USES THEREOF IN THE TREATMENT OF CANCER | GENENTECH, INC. (US) | 2022-10-13 | — | — | WO | disclosed |
| US-20220306640-A1 | HYDANTOIN DERIVATIVE | ONO PHARMACEUTICAL CO., LTD. (JP) | 2022-09-29 | — | — | US | disclosed |
| US-20210300900-A1 | OGA INHIBITOR COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2021-09-30 | — | — | US | disclosed |
| EP-1844044-B1 | THIAZOLE-4-CARBOXAMIDE DERIVATIVES AS MGLUR5 ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2010-07-21 | — | — | EP | disclosed |
| US-7678815-B2 | Thiazole-4-carboxyamide derivatives | HOFFMANN-LA ROCHE INC. (US) | 2010-03-16 | — | — | US | disclosed |
| EP-1844044-A1 | THIAZOLE-4-CARBOXAMIDE DERIVATIVES AS MGLUR5 ANTAGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2007-10-17 | — | — | EP | disclosed |
| US-20060160857-A1 | Thiazole-4-carboxyamide derivatives | HOFFMANN-LA ROCHE INC. | 2006-07-20 | — | — | US | disclosed |
| WO-2006074884-A1 | THIAZOLE-4-CARBOXAMIDE DERIVATIVES AS MGLUR5 ANTAGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2006-07-20 | — | — | WO | disclosed |
| EP-1652839-A2 | Drug efflux pump inhibitor | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2006-05-03 | — | — | EP | disclosed |
| EP-1227084-B1 | DRUG DISCHARGE PUMP INHIBITORS | TRINE PHARMACEUTICALS INC (US) | 2005-12-14 | — | — | EP | disclosed |
| EP-1227084-A1 | DRUG DISCHARGE PUMP INHIBITORS | Microcide Pharmaceuticals, Inc. (US) | 2002-07-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060160857-A1 | Thiazole-4-carboxyamide derivatives | GRM1, GRM2, GRIA4 | NAMPT 3415/4885CYP17A1 3752/4885RAB9A 3231/4885 |
| US-20210300900-A1 | OGA INHIBITOR COMPOUNDS | OGA, OGT, GRN | NAMPT 492/4885CYP17A1 3691/4885RAB9A 2809/4885 |
| US-20240383915-A1 | OXAZEPINE COMPOUNDS AND USES THEREOF IN THE TREATMENT OF CANCER | OXA1L, GRIK4, GRIK5 | NAMPT 278/4885CYP17A1 1021/4885RAB9A 3939/4885 |
| US-20220306640-A1 | HYDANTOIN DERIVATIVE | DDR1, DDR2, DDRGK1 | NAMPT 2004/4885CYP17A1 4739/4885RAB9A 2089/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.